Thyroidectomy with neoadjuvant PLX4720 extends survival and decreases tumor burden in an orthotopic mouse model of anaplastic thyroid cancer

Surgery

Volumn 148, Issue 6, 2010, Pages 1154-1162

  Nehs, Matthew A ^a   Nagarkatti, Sushruta ^a   Nucera, Carmelo ^a   Hodin, Richard A ^a   Parangi, Sareh ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE INHIBITOR; KI 67 ANTIGEN; PLX 4720; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ANAPLASTIC CARCINOMA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CACHEXIA; CANCER INVASION; CANCER SURVIVAL; CONTROLLED STUDY; HISTOPATHOLOGY; LUNG METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; SHAM PROCEDURE; THYROID CANCER; THYROIDECTOMY; TUMOR GROWTH; TUMOR VOLUME; WEIGHT REDUCTION;

ANIMALS; BODY WEIGHT; CELL DIVISION; COMBINED MODALITY THERAPY; COST OF ILLNESS; DISEASE MODELS, ANIMAL; INDOLES; MICE; NEOADJUVANT THERAPY; NEOPLASM STAGING; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTO-ONCOGENE PROTEINS B-RAF; SULFONAMIDES; THYROID NEOPLASMS; THYROIDECTOMY;

EID: 78649949456     PISSN: 00396060     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.surg.2010.09.001     Document Type: Article

References (16)

1. R.L. Neff, W.B. Farrar, R.T. Kloos, and K.D. Burman Anaplastic thyroid cancer Endocrinol Metab Clin North Am 37 2008 525 538
2. A. Pichardo-Lowden, S. Durvesh, S. Douglas, W. Todd, M. Bruno, and D. Goldenberg Anaplastic thyroid carcinoma in a young woman: a rare case of survival Thyroid 19 2009 775 779
3. C. Are, and A.R. Shaha Anaplastic thyroid carcinoma: biology, pathogenesis, prognostic factors, and treatment approaches Ann Surg Oncol 13 2006 453 464
4. J.L. Pasieka Anaplastic thyroid cancer Curr Opin Oncol 15 2003 78 83
5. J.A. Fagin Molecular genetics of human thyroid neoplasms Ann Rev Med 45 1994 45 52
6. S. Begum, E. Rosenbaum, R. Henrique, Y. Cohen, D. Sidransky, and W.H. Westra BRAF mutations in anaplastic thyroid carcinoma: implications for tumor origin, diagnosis and treatment Mod Pathol 17 2004 1359 1363
7. Y.S. Venkatesh, N.G. Ordonez, P.N. Schultz, R.C. Hickey, H. Goepfert, and N.A. Samaan Anaplastic carcinoma of the thyroid. A clinicopathologic study of 121 cases Cancer 66 1990 321 330
8. C. Nucera, M. Goldfarb, R. Hodin, and S. Parangi Role of B-Raf(V600E) in differentiated thyroid cancer and preclinical validation of compounds against B-Raf(V600E) Biochim Biophys Acta 1795 2009 152 161
9. M. Xing BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications Endocr Rev 28 2007 742 762
10. J. Tsai, J.T. Lee, W. Wang, J. Zhang, H. Cho, and S. Mamo Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity Proc Natl Acad Sci U S A 105 2008 3041 3046
11. R.A. Cartlidge, G.R. Thomas, S. Cagnol, K.A. Jong, S.A. Molton, and A.J. Finch Oncogenic BRAF(V600E) inhibits BIM expression to promote melanoma cell survival Pigment Cell Melanoma Res 21 2008 534 544
12. P. Salerno, V. De Falco, and A. Tamburrino Cytostatic activity of adenosine triphosphate-competitive kinase inhibitors in BRAF mutant thyroid carcinoma cells J Clin Endocrinol Metab 95 2010 450 455
13. C. Nucera, M.A. Nehs, M. Mekel, T.C. Nappi, G. Vecchio, and R.E. Schweppe A novel orthotopic mouse model of human anaplastic thyroid carcinoma Thyroid 19 2009 1077 1084
14. G. Hatzivassiliou, K. Song, I. Yen, B.J. Brandhuber, D.J. Anderson, and R. Alvarado RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth Nature 464 2010 431 435
15. P.I. Poulikakos, C. Zhang, G. Bollag, K.M. Shokat, and N. Rosen RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF Nature 464 2010 427 430
16. Heidorn SJ, Milagre C, Whittaker S, Nourry A, Niculescu-Duvas I, Dhomen N, et al. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell;140:209-221.